Abatacept

Summary

Abatacept (CHEMBL1201823) is an approved protein (ATC L04AA24) targeting CD80 and CD86; indicated across 46 conditions including rheumatoid arthritis and psoriatic arthritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L04AA24
• Targets: 2 (CD80, CD86)
• Indications: 46 conditions
• Clinical trials: 186

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201823
Name	Abatacept
Type	Protein
Max phase	4
ATC	L04AA24

Also known as: Abatacept, Abatacept (genetical recombination), Abatacept recombinant, BMS-188667, Orencia, Orencia clickject, RG-1046, RG-2077, ABATACEPT

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD80	CD80	Inhibition	7.92	0.2%	P33681
CD86	CD86	Inhibition	7.92	0.4%	P42081

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): CD80, CD86.

Top Reactome pathways

19 total, by targets touching each:

Pathway	Targets	Genes
PIP3 activates AKT signaling	2	CD80, CD86
Cytokine Signaling in Immune system	2	CD80, CD86
Adaptive Immune System	2	CD80, CD86
Signal Transduction	2	CD80, CD86
Disease	2	CD80, CD86
Immune System	2	CD80, CD86
Negative regulation of the PI3K/AKT network	2	CD80, CD86
PI3K/AKT Signaling in Cancer	2	CD80, CD86
Constitutive Signaling by Aberrant PI3K in Cancer	2	CD80, CD86
Regulation of T cell activation by CD28 family	2	CD80, CD86
Co-stimulation by CD28	2	CD80, CD86
CD28 dependent PI3K/Akt signaling	2	CD80, CD86
CD28 dependent Vav1 pathway	2	CD80, CD86
Co-inhibition by CTLA4	2	CD80, CD86
Signaling by Interleukins	2	CD80, CD86
Diseases of signal transduction by growth factor receptors and second messengers	2	CD80, CD86
Interleukin-10 signaling	2	CD80, CD86
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	2	CD80, CD86
Intracellular signaling by second messengers	2	CD80, CD86

Dominant GO biological processes

GO term	Targets
immune response	2
cell surface receptor signaling pathway	2
T cell costimulation	2
positive regulation of interleukin-2 production	2
positive regulation of T cell proliferation	2
T cell activation	2
negative regulation of T cell proliferation	2
positive regulation of DNA-templated transcription	2
negative regulation of T cell receptor signaling pathway	2
positive regulation of T cell receptor signaling pathway	2
negative regulation of T cell activation	2
cellular response to lipopolysaccharide	2
immune system process	2
symbiont entry into host cell	2
negative regulation of T cell mediated immunity	1

Indications & clinical

Indications

5 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
rheumatoid arthritis	4	MONDO:0008383	EFO:0000685
psoriatic arthritis	4	MONDO:0011849	EFO:0003778
juvenile idiopathic arthritis	4	MONDO:0011429	EFO:0002609
immune system disorder	4	MONDO:0005046	EFO:0000540
polyarticular juvenile idiopathic arthritis	4	MONDO:0018456	EFO:0009730

34 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Crohn disease	3	MONDO:0005011	EFO:0000384
ulcerative colitis	3	MONDO:0005101	EFO:0000729
granulomatosis with polyangiitis	3	MONDO:0012105	EFO:0005297
anti-neutrophil antibody associated vasculitis	3	MONDO:0005435	EFO:0004826
dermatomyositis	3	MONDO:0016367	EFO:0000398
Sjogren syndrome	3	MONDO:0010030	EFO:0000699
lupus nephritis	3	MONDO:0005556	EFO:0005761
temporal arteritis	3	MONDO:0008538	EFO:1001209
polymyalgia rheumatica	3	MONDO:0019735	EFO:0008518
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
diffuse scleroderma	2	MONDO:0005019	EFO:0000404
ankylosing spondylitis	2	MONDO:0005306	EFO:0003898
hypertensive disorder	2	MONDO:0005044	EFO:0000537
alopecia areata	2	MONDO:0005340	EFO:0004192
psoriasis	2	MONDO:0005083	EFO:0000676
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
nephrotic syndrome	2	MONDO:0005377	EFO:0004255
uveitis	2	MONDO:0020283	EFO:1001231
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
Takayasu arteritis	2	MONDO:0017991	EFO:1001857
graft versus host disease	2	MONDO:0013730	MONDO:0013730
myocarditis	2	MONDO:0004496	EFO:0009609
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
multiple sclerosis	2	MONDO:0005301	MONDO:0005301
sarcoidosis	2	MONDO:0019338	MONDO:0019338
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
alopecia	2	MONDO:0004907	MONDO:0019080
polymyositis	2	MONDO:0019127	EFO:0003063
vitiligo	1	MONDO:0008661	EFO:0004208
relapsing polychondritis	1	MONDO:0019125	EFO:1001148
thalassemia	1	MONDO:0000984	EFO:1001996
systemic sclerosis	1	MONDO:0005100	EFO:0000717
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976
sickle cell disease	1	MONDO:0011382	MONDO:0011382

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 186.

Phase distribution

Phase	Trials
PHASE2	52
PHASE3	48
PHASE4	22
PHASE1	20
Not specified	19
PHASE1/PHASE2	15
EARLY_PHASE1	6
PHASE2/PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01000441	PHASE4	COMPLETED	Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
NCT01295151	PHASE4	COMPLETED	SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
NCT01491815	PHASE4	UNKNOWN	Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction
NCT01557374	PHASE4	COMPLETED	TOward the Lowest Effective DOse of Abatacept or Tocilizumab
NCT01638715	PHASE4	COMPLETED	A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
NCT01758198	PHASE4	COMPLETED	Abatacept Post-marketing Clinical Study in Japan
NCT02078882	PHASE4	COMPLETED	Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
NCT02353780	PHASE4	TERMINATED	Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept
NCT02466581	PHASE4	UNKNOWN	Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity
NCT02557100	PHASE4	COMPLETED	Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis
NCT02594735	PHASE4	COMPLETED	Abatacept in Juvenile Dermatomyositis
NCT02652273	PHASE4	UNKNOWN	Inhibition of Co-Stimulation in Rheumatoid Arthritis
NCT03492658	PHASE4	COMPLETED	Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)
NCT03619876	PHASE4	TERMINATED	Effects of Abatacept on Myocarditis in Rheumatoid Arthritis
NCT03652961	PHASE4	COMPLETED	Rheumatoid Arthritis Memory B Cells and Abatacept
NCT03669367	PHASE4	COMPLETED	EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)
NCT03737708	PHASE4	COMPLETED	A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)
NCT03882008	PHASE4	COMPLETED	A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
NCT04106804	PHASE4	UNKNOWN	Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker
NCT04255134	PHASE4	COMPLETED	Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
NCT05080218	PHASE4	COMPLETED	COVID-19 VaccinE Response in Rheumatology Patients
NCT05822583	PHASE4	COMPLETED	Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
NCT03414502	PHASE3	RECRUITING	Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT04474847	PHASE3	RECRUITING	Abatacept for the Treatment of Giant Cell Arteritis
NCT04909801	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT05335928	PHASE3	RECRUITING	Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05428488	PHASE3	RECRUITING	Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
NCT05515029	PHASE3	ACTIVE_NOT_RECRUITING	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT06654882	PHASE3	RECRUITING	Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis
NCT07366801	PHASE2/PHASE3	RECRUITING	Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
NCT00048568	PHASE3	COMPLETED	A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
NCT00048581	PHASE3	COMPLETED	Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
NCT00048932	PHASE3	COMPLETED	A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
NCT00095173	PHASE3	COMPLETED	BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
NCT00122382	PHASE3	COMPLETED	Remission and Joint Damage Progression in Early Rheumatoid Arthritis
NCT00124982	PHASE3	COMPLETED	Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
NCT00406653	PHASE3	TERMINATED	A Study of Abatacept in Patients With Active Crohn’s Disease
NCT00409838	PHASE3	COMPLETED	A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
NCT00410410	PHASE3	COMPLETED	A Study of Abatacept in Patients With Active Ulcerative Colitis
NCT00420199	PHASE3	COMPLETED	A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
NCT00430677	PHASE2/PHASE3	TERMINATED	Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT00484289	PHASE3	COMPLETED	A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
NCT00533897	PHASE3	COMPLETED	Phase IIIB Subcutaneous Missed Dose Study
NCT00547521	PHASE3	COMPLETED	Phase IIIB Subcutaneous Abatacept Monotherapy Study
NCT00559585	PHASE3	COMPLETED	Methotrexate-Inadequate Response Study
NCT00663702	PHASE3	COMPLETED	Phase IIIB Switching From Intravenous to Subcutaneous Study
NCT00767325	PHASE3	COMPLETED	A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
NCT00929864	PHASE3	COMPLETED	Abatacept Versus Adalimumab Head-to-Head
NCT00989235	PHASE3	COMPLETED	Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis
NCT01001832	PHASE2/PHASE3	COMPLETED	Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients
NCT01142726	PHASE3	COMPLETED	Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis
NCT01299961	PHASE3	COMPLETED	Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
NCT01333878	PHASE2/PHASE3	COMPLETED	Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
NCT01350804	PHASE3	COMPLETED	Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
NCT01351480	PHASE3	COMPLETED	Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
NCT01714817	PHASE3	TERMINATED	Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
NCT01835470	PHASE3	COMPLETED	Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
NCT01844518	PHASE3	COMPLETED	Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
NCT01844895	PHASE3	COMPLETED	Methotrexate-Inadequate Response Autoinjector Device Sub Study
NCT01860976	PHASE3	COMPLETED	Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis
NCT02108860	PHASE3	COMPLETED	Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s)
NCT02504268	PHASE3	COMPLETED	Effects of Abatacept in Patients With Early Rheumatoid Arthritis
NCT02722694	PHASE3	UNKNOWN	A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
NCT02778906	PHASE3	COMPLETED	Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia
NCT02840175	PHASE3	COMPLETED	Treatment Tapering in JIA With Inactive Disease
NCT02915159	PHASE3	COMPLETED	A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome
NCT02971683	PHASE3	COMPLETED	Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
NCT03086343	PHASE3	COMPLETED	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
NCT03192969	PHASE3	WITHDRAWN	A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
NCT03632187	PHASE3	UNKNOWN	Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS
NCT03841357	PHASE3	COMPLETED	Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
NCT04593940	PHASE3	COMPLETED	Immune Modulators for Treating COVID-19
NCT04610476	PHASE3	UNKNOWN	Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
NCT05451615	PHASE3	UNKNOWN	Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
NCT03924401	PHASE2	ACTIVE_NOT_RECRUITING	Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
NCT03929601	PHASE2	ACTIVE_NOT_RECRUITING	Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT04380740	PHASE2	RECRUITING	Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
NCT04925375	PHASE2	RECRUITING	Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
NCT04955366	PHASE2	ACTIVE_NOT_RECRUITING	Abatacept Conversion in Kidney Transplantation
NCT05195645	PHASE2	ACTIVE_NOT_RECRUITING	AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
NCT05289167	PHASE1/PHASE2	RECRUITING	Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
NCT05426252	PHASE1/PHASE2	RECRUITING	Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
NCT05621759	PHASE2	ACTIVE_NOT_RECRUITING	Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
NCT05917522	PHASE2	RECRUITING	Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
NCT06145282	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function
NCT06680661	PHASE2	RECRUITING	ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
NCT06681922	PHASE1/PHASE2	RECRUITING	A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT06859424	PHASE2	RECRUITING	A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT07138898	PHASE2	NOT_YET_RECRUITING	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07238712	PHASE2	RECRUITING	Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
NCT07599176	PHASE1/PHASE2	RECRUITING	Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
NCT00094380	PHASE1/PHASE2	COMPLETED	Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
NCT00119678	PHASE2	COMPLETED	Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
NCT00124449	PHASE2	COMPLETED	Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients
NCT00162266	PHASE2	COMPLETED	Abatacept With Methotrexate- Phase IIB
NCT00162279	PHASE2	COMPLETED	The Study of Abatacept in Combination With Etanercept
NCT00254293	PHASE1/PHASE2	COMPLETED	Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
NCT00276250	PHASE2	COMPLETED	Islet Transplantation Using Abatacept
NCT00279760	PHASE1/PHASE2	COMPLETED	Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis
NCT00287547	PHASE2	COMPLETED	Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).